The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET+) NSCLC.
 
Theresa Bayt
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Jonathan W. Goldman
Consulting or Advisory Role - AbbVie; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Gritstone Bio; Jazz Pharmaceuticals; Regeneron; Summit Biomedical
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Pfizer (Inst); Summit Biomedical (Inst)
 
Jacob Sands
Honoraria - Pfizer
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/UCB Japan; G1 Therapeutics; Gilead Sciences; Guardant Health; Lilly; Medtronic; PharmaMar; Sanofi
Research Funding - Amgen; Harpoon
Travel, Accommodations, Expenses - AstraZeneca
 
Andreas Hallqvist
Research Funding - Novartis
 
Hye Ryun Kim
Speakers' Bureau - ABL Bio; Ono Pharmaceutical; Roche/Genentech
 
Guoping Li
No Relationships to Disclose
 
Lin Wu
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Hengrui Medicine; Innovate Biopharmaceuticals; Lilly; MSD; Pfizer; Roche China
 
Weiji Su
Employment - Lilly
 
Xue-Ning Yang
No Relationships to Disclose
 
Maximilian Hochmair
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Lilly; Roche; Takeda
Speakers' Bureau - Lilly; MSD Oncology; Novartis; Roche